ASH 2020 | Treating advanced follicular lymphoma progressive or relapsed after R2
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of a retrospective study examining management strategies and outcomes for patients with advanced follicular lymphoma which has relapsed or progressed after frontline lenalidomide and rituximab therapy (R2). Post-relapse salvage therapy achieved an overall response rate (ORR) of 78% and median progression-free survival (PFS) was significantly longer for patients who received chemoimmunotherapy compared with biological therapy. These findings suggest that chemoimmunotherapy is an effective treatment strategy for advanced follicular lymphoma patients who relapsed after an initial R2 treatment. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
